DEFEATING DEMENTIA:

NEW DIRECTIONS FROM THE BIOLOGY OF AGING

 

April 13, 2023 | Bakar Labs, Berkeley, CA | By invitation only

 

BACKGROUND

The recent progress in developing treatments for Alzheimer’s and other dementias has created new momentum to accelerate progress by convening the academic and private sector expertise of the San Francisco Bay Area to discuss new and emerging approaches for treatment and prevention.

  • Attract and cultivate new talent in the field

  • Promote successful entrepreneurship in therapies and diagnostics

  • Stimulate cross-fertilization of ideas and technologies across disciplines

We are launching this initiative by holding an invitation-only symposium at UC Berkeley’s new life science incubator, Bakar Labs, on Thursday, April 13, 2023.

AUDIENCE

This event anticipates attracting 200-300 delegates spanning from investors, entrepreneurs, non-profits, government bodies, academia, innovation directors, therapy area heads, CSOs, CMOs, and business development managers from biotech and pharma, and many others!

VENUE

All sessions will be held at Bakar Labs, located at 2625 Durant Ave., Berkeley, CA 94704.

SYMPOSIUM GOALS:

1

Stimulate new thinking on brain disease by hearing of pertinent work on other aging-related diseases such as cancer

2

Promote the development of a Bay Area ecosystem of researchers, investors, and companies in the dementia-related space

3

Hear of novel approaches for dementia coming from top Bay Area labs, academic and private sector

4

Recruit innovators into the space by having a start-up competition for resource awards

5

Encourage motivated Bay Area students to consider a career in the space

6

Enlighten the community about the entrepreneurial support services available in Bakar Labs, ADDF and elsewhere

PROGRAM

All sessions will be held at Bakar Labs located at 2625 Durant Ave, Berkeley, CA 94704.

7:30 am

SESSION

Check-in and Breakfast

PRESENTER

8:00

SESSION

Optional Bakar Labs Tour

PRESENTER

8:30

SESSION

Welcome address

PRESENTER

Regis Kelly, PhD, Bakar Labs
Howard Fillit, MD, ADDF

8:45

SESSION

KEYNOTE: Progress in the biology of aging and dementia

PRESENTER

Tony Wyss-Coray, PhD, Stanford University

9:15

SESSION

Discussion

PRESENTER

9:30-10:30

SESSION

SESSION: EVOLVING CONCEPTS OF DEMENTIA

PRESENTER

CHAIR: Meriel Owen, PhD, ADDF

9:30

SESSION

Session Overview

PRESENTER

Chair

9:35

SESSION

Lecture

PRESENTER

Ryan Watts, PhD, Denali

9:50

SESSION

Understanding epigenetic regulators of the aging process

PRESENTER

Eric Verdin, MD, Buck Institute

10:05

SESSION

Molecular mechanisms behind BBB opening and its consequences

PRESENTER

Daniela Kaufer, PhD, UC Berkeley

10:20

SESSION

Break

PRESENTER

10:40

SESSION

Synaptogenesis during aging and its response to ISRIB

PRESENTER

Susanna Rosi, PhD, Altos Labs

10:55

SESSION

Neuroimmunology as a strategy for targeting neurodegeneration

PRESENTER

Sara Kenkare-Mitra, PhD, Alector

11:10

SESSION

Mechanisms of neurodegeneration in Parkinson’s disease

PRESENTER

Suzanne Pfeffer, PhD, Stanford University

11:25

SESSION

Glia: controls on beneficial and toxic states in disease

PRESENTER

Martin Kampmann, PhD, UCSF

11:40

SESSION

Aging, lysosomes and neurodegenerative disease

PRESENTER

Aimee Kao, MD, PhD, UCSF

11:55

SESSION

Discussion

PRESENTER

12:25 pm

SESSION

Lunch

PRESENTER

1:30-5:15

SESSION

DEMENTIA INNOVATION SHOWCASE

PRESENTER

CHAIR: Meriel Owen, PhD, ADDF

1:30

SESSION

Session Overview

PRESENTER

Chair

1:35

SESSION

Bakar Labs

PRESENTER

Regis Kelly, PhD, Bakar Labs

1:45

SESSION

Alzheimer’s Drug Discovery Foundation Funding Opportunities

PRESENTER

Meriel Owen, PhD, ADDF

1:55-3:10

SESSION

Presentations from the ADDF Portfolio

PRESENTER

ADDF Portfolio

3:10

SESSION

Break

PRESENTER

3:30-5:15

SESSION

Presentations from selected submissions

PRESENTER

Startup Forum

5:15-5:55

SESSION

PANEL: MOVING TOWARDS PRECISION MEDICINE

PRESENTER

CHAIR: Regis Kelly, PhD, Bakar Labs

5:55

SESSION

Concluding Remarks

PRESENTER

Mark Roithmayr, ADDF

6:00-7:00

SESSION

NETWORKING RECEPTION

PRESENTER

6:30

SESSION

Award Ceremony

PRESENTER

INNOVATION SHOWCASE

The symposium’s program invites applications from start-up companies to present for 15 minutes (10-minute pitch and 5-minute Q&A with the audience). This is an opportunity for start-up companies to showcase their research and present to an audience of representatives from industry, investment, and university communities.

 

Eight companies will be selected to present their technologies in the symposium’s Dementia Innovation Startup Showcase. All stage companies are invited to apply. Early spin-outs are encouraged, especially those with need for lab space.

 

The application deadline is Friday, March 3, 2023, 11:59 PT.

 

All applications will be reviewed by the program committee and results will be communicated by email on or around March 17.
Presentations will be evaluated onsite by a panel of judges, who will select a winner to be announced during the networking reception concluding the symposium.

REQUEST YOUR SEAT AT THE SYMPOSIUM


SYMPOSIUM PARTNERS

QB3/Bakar Labs

QB3 is the University of California’s hub for innovation and entrepreneurship in life science. The institute supports UC researchers and empowers California founders to launch startup companies and partner with industry.

QB3 has a 20-year track record of spinning off innovative endeavors such as the venture capital firms Mission Bay Capital and Medtech Venture Partners; several incubators, including QB3@953 (now part of MBC Biolabs); and a health technology initiative, the UCSF Rosenman Institute.

QB3 founded and operates Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub. Companies affiliated with QB3 brought in $942 million in funding in 2022.

https://qb3.org

Alzheimer’s Drug Discovery Foundation

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry.

The ADDF’s leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer’s PET scan (Amyvid™) and blood test (PrecivityAD™) to market, as well as fueling the current robust and diverse drug pipeline.

Through the generosity of its donors, the ADDF has awarded nearly $250 million to fund over 720 Alzheimer’s drug discovery programs, biomarker programs and clinical trials in 19 countries.

https://alzdiscovery.org

CONTACT

Program: Regis Kelly, PhD (Regis.Kelly@ucsf.edu) and Meriel Owen, PhD (mowen@alzdiscovery.org).

Partnerships and Logistics: Riley Hummel (rileyhummel@berkeley.edu)

Registrations: meetings@alzdiscovery.org